A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
The main purpose of this study is to evaluate the efficacy and safety of GB491 combined with Letrozole versus placebo combined with Letrozole in the treatment of HR+/HER2- locally advanced or metastatic breast cancer without prior systemic antitumor therapy
Breast Cancer
DRUG: GB491 combined with Letrozole|DRUG: Placebo combined with Letrozole
Investigator-assessed PFS based on RECIST v1.1, To evaluate progression-free survival (PFS) of GB491 plus Letrozole versus placebo plus Letrozole in HR+/HER2- locally advanced or metastatic breast cancer without prior systemic antitumor therapy (as assessed by the investigator)., Approximately 60 months
BICR-assessed PFS based on RECIST v1.1., Approximately 60 months|OS, Approximately 60 months|ORR, Approximately 60 months|DOR, Approximately 60 months|DCR, Approximately 60 months|CBR, Approximately 60 months|Number of Participants With adverse events (AEs) and serious adverse events (SAEs) Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0, Approximately 60 months
The main purpose of this study is to evaluate the efficacy and safety of GB491 combined with Letrozole versus placebo combined with Letrozole in the treatment of HR+/HER2- locally advanced or metastatic breast cancer without prior systemic antitumor therapy